Logo

GenEdit and Genentech Partner for the Discovery and Development of Novel Nanoparticles to Treat Autoimmune Diseases

Share this
Genentech

GenEdit and Genentech Partner for the Discovery and Development of Novel Nanoparticles to Treat Autoimmune Diseases

Shots:

  • GenEdit and Genentech have signed a multiyear collaboration and license agreement for the discovery and development of hydrophilic nanoparticles (HNPs) to design nucleic acid-based therapies for autoimmune diseases by utilizing the former’s NanoGalaxy platform
  • As per the agreement, preclinical, clinical, regulatory development and commercialization of products resulting from the use of GenEdit’s nanoparticles will be carried out by Genentech
  • Furthermore, GenEdit will be eligible to receive $15M as an upfront payment and near-term, preclinical, clinical development, commercial & net sales milestone payments of up to $629M along with tiered royalties on net global sales

Ref: GenEdit | Image: Genentech

Related News:- Celltrion Reports Preliminary Results from the P-III Clinical Trial of CT-P39 (biosimilar, omalizumab) for Allergic Asthma and Chronic Urticaria

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions